Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | University of Pittsburgh | 15 |
| 2 | Tanabe Pharma Corp | 5 |
| 3 | Incyte Corp | 1 |
| 4 | Mount Sinai Health System Inc | 1 |
| 5 | Neurocrine Biosciences Inc | 1 |
| 6 | Universität Bielefeld | 1 |
| 7 | Yale University | 1 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 25 |
| 2 | A61K | Medicinal preparations | 20 |
| 3 | C07D | Heterocyclic compounds | 15 |
| 4 | C07K | Peptides | 7 |
| 5 | C07C | Acyclic and carbocyclic compounds | 6 |
| 6 | A01K | 3 | |
| 7 | A61Q | Cosmetics, personal care | 3 |
| 8 | C07F | Organometallic compounds | 3 |
| 9 | C12N | Microorganisms, enzymes | 3 |
| 10 | C08G | Polymers from non-vinyl bonds (e.g. polyamides, polyesters) | 1 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Heterocyclylamines as PI3K inhibitors | 2022 | Incyte Corp | 3 |
| INTRAESOPHAGEAL ADMINISTRATION OF TARGETED NITROXIDE AGENTS FOR PROTECTION AGAINST IONIZING IRRADIATION-INDUCED ESOPHAGATIS | 2012 | University of Pittsburgh | 9 |
| Benzopyran compound and its pharmaceutical use | 1989 | Tanabe Pharma Corp | 22 |
| Benzopyran compound and its pharmaceutical use | 1991 | Tanabe Pharma Corp | 20 |
| Targeted nitroxide agents | 2013 | University of Pittsburgh | 6 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Hidenari Sakuta | National Defense Medical College | 9 |
| 2 | Masatoshi Fujishima | Kyushu University | 6 |
| 3 | Takanari Kitazono | Kyushu University | 5 |
| 4 | Koichi Okamoto | National Defense Medical College | 5 |
| 5 | Setsuro Ibayashi | Kyushu University | 5 |
| 6 | T Nagao | Kyushu University | 4 |
| 7 | Hikaru Suzuki | Nagoya City University | 3 |
| 8 | Adam Yasgar | National Institutes of Health | 2 |
| 9 | Atsushi Fukunari | Kyoto Pharmaceutical Industries (Japan) | 2 |
| 10 | Kenji Shinagawa | Kyoto Pharmaceutical Industries (Japan) | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Suppression of airway hyperresponsiveness induced by ovalbumin sensitisation and RSV infection with Y-27632, a Rho kinase inhibitor | 2002 | 64 | Asthma and respiratory diseases |
| RhoA mediates defective stem cell function and heterotopic ossification in dystrophic muscle of mice | 2013 | 42 | Muscle Physiology and Disorders |
| Antiarrhythmic drugs, clofilium and cibenzoline are potent inhibitors of glibenclamide‐sensitive K+ currents in Xenopus oocytes | 1993 | 33 | Neuroscience and Neuropharmacology Research |
| Calcitonin gene-related peptide affords gastric mucosal protection by activating potassium channel in Wistar rat | 1998 | 32 | Heart Failure Treatment and Management |
| Altered Cerebrovascular Response to a Potassium Channel Opener in Hypertensive Rats | 1996 | 31 | Neuroscience and Neuropharmacology Research |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Y 26763?
Which organizations hold the most patents related to Y 26763?
What are the primary research applications covered by patents for Y 26763?
How has patent activity for Y 26763 trended in recent years?
Who are the most prolific authors publishing research on Y 26763?